Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China

Table 1 AIC and BIC of OS curve and PFS curve in the Sintilimab group and chemotherapy group (mle)

group	exponential		gamma		genf		gengamma
group	AIC	BIC	AIC	BIC	AIC	BIC	AIC	BIC
OS curve(sintilimab-combination group)	496.88	500.46	487.56	494.73	491.22	505.55	489.22	499.97
OS curve(placebo-combination group)	333.26	336.14	328.12	333.87	329.21	340.71	327.21	335.84
PFS curve(sintilimab-combination group)	823.26	826.84	807.58	814.74	809.64	823.97	807.64	818.39
PFS curve(placebo-combination group)	513.02	515.89	489.20	494.95	491.40	502.90	489.40	498.03
group	weibull		weibullPH		loglogistic		lognormal
group	AIC	BIC	AIC	BIC	AIC	BIC	AIC	BIC
OS curve(sintilimab-combination group)	487.83	494.99	487.83	494.99	487.73	494.90	487.30	494.47
OS curve(placebo-combination group)	328.95	334.70	328.95	334.70	327.80	333.55	325.84	331.59
PFS curve(sintilimab-combination group)	808.83	816.00	808.83	816.00	807.72	814.89	805.67	812.84
PFS curve(placebo-combination group)	491.88	497.63	491.88	497.63	488.61	494.36	487.54	493.29

ISSN: 2191-1991